Valvular & structural heart diseaseCohort study
Temporal Trends in Transcatheter Tricuspid Valve Interventions After FDA Approval in the United States
- retrospective cohort study
Authors' conclusion
There is increased adoption of both T-TEER and TTVR in early commercial experience with clinical characteristics of treated patients similar to those enrolled in pivotal trials. In-hospital outcomes were overall favorable supporting the generalizability of the pivotal trial findings to contemporary practice.
Study context
- Population
- Patients who underwent Transcatheter Tricuspid Edge-to-edge Repair (T-TEER) or Transcatheter Tricuspid Valve Replacement (TTVR) in the Vizient Clinical Data Base between October 2024 and December 2025procedures · T-TEER procedures (180 implanting hospitals) 2,143 · TTVR procedures (113 implanting hospitals) 1,301
- Participants
- 2,143 vs 1,301
- Exposure
- T-TEER vs TTVR
- T-TEERn = 2,143
- TTVRn = 1,301
Main finding
As reported in the abstract
Median annualized hospital volume
T-TEER
6.4
median · IQR 2.4–13.6
TTVR
6.4
median · IQR 3.2–11.2
Observational data: associations, not effects.
Further findings
| Outcome | T-TEER | TTVR |
|---|---|---|
| Overall monthly volumes · October 2024 to December 2025 | 128 in October 2024 to 156 in December 2025 | 60 in October 2024 to 111 in December 2025 |
- Overall monthly volumes: T-TEER P for trend = 0.004
- Overall monthly volumes: TTVR P for trend <0.001
Proportion of TTVR among all TTVI
- increased over time
- from 31.9% to 41.6%
- P for trend = 0.006
Baseline patient comorbidities
- similar to pivotal trial populations
Safety
In-hospital mortality
Major bleeding
| Outcome | T-TEER | TTVR |
|---|---|---|
| New pacemaker implantation | Not reported in the abstract | 11.3% |
Original publication
Temporal Trends in Transcatheter Tricuspid Valve Interventions After FDA Approval in the United States. JACC Adv. Published 23 September 2026. doi:10.1016/j.jacadv.2026.103266
Summarised from the published abstract; every number is checked against it